NO20072435L - CGRP-reseptorantagonister - Google Patents
CGRP-reseptorantagonisterInfo
- Publication number
- NO20072435L NO20072435L NO20072435A NO20072435A NO20072435L NO 20072435 L NO20072435 L NO 20072435L NO 20072435 A NO20072435 A NO 20072435A NO 20072435 A NO20072435 A NO 20072435A NO 20072435 L NO20072435 L NO 20072435L
- Authority
- NO
- Norway
- Prior art keywords
- receptor antagonists
- cgrp receptor
- cgrp
- compounds
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
Abstract
Forbindelser med formel (I) og formel (II): som definert i beskrivelsen, er anvendelige som antagonister av CGRPreseptorer og ved behandling eller forhindring av sykdommer hvor CGRP er involvert, som hodepine, migrene og klasehodepine. Det beskrives ogsa farmasøytiske preparater omfattende disse forbindelser og anvendel se av disse forbindelser og preparater ved forhindring eller behandling av slike sykdommer hvor CGRP er involvert.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61845104P | 2004-10-13 | 2004-10-13 | |
US68383705P | 2005-05-24 | 2005-05-24 | |
PCT/US2005/036763 WO2006044504A1 (en) | 2004-10-13 | 2005-10-12 | Cgrp receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072435L true NO20072435L (no) | 2007-07-12 |
Family
ID=35705270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072435A NO20072435L (no) | 2004-10-13 | 2007-05-11 | CGRP-reseptorantagonister |
Country Status (14)
Country | Link |
---|---|
US (1) | US8039460B2 (no) |
EP (1) | EP1802637B1 (no) |
JP (1) | JP4913061B2 (no) |
KR (1) | KR20070062997A (no) |
AT (1) | ATE411323T1 (no) |
AU (1) | AU2005295729B2 (no) |
BR (1) | BRPI0517418A (no) |
CA (1) | CA2583536A1 (no) |
DE (1) | DE602005010463D1 (no) |
IL (1) | IL182317A0 (no) |
MX (1) | MX2007004393A (no) |
NO (1) | NO20072435L (no) |
RU (1) | RU2007117741A (no) |
WO (1) | WO2006044504A1 (no) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1799672B1 (en) * | 2004-10-07 | 2013-01-02 | Merck Sharp & Dohme Corp. | Cgrp receptor antagonists |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
ATE517903T1 (de) | 2006-05-02 | 2011-08-15 | Bristol Myers Squibb Co | Verbindungen mit eingeschränkter konformation als cgrp rezeptor antagonisten. |
US7470680B2 (en) | 2006-05-03 | 2008-12-30 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
BRPI0711352A2 (pt) | 2006-05-09 | 2011-09-27 | Merck & Co Inc | composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular |
KR20170091770A (ko) | 2006-07-10 | 2017-08-09 | 파이온 유케이 리미티드 | 속효형 벤조디아제핀 염 및 이의 중합체 형태 |
GB0712392D0 (en) * | 2007-06-26 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
GB0725103D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Novel compounds |
EP2254413A4 (en) * | 2008-02-19 | 2011-10-26 | Merck Sharp & Dohme | IMIDAZOBENZAZEPIN-CGRP receptor antagonists |
US8044043B2 (en) * | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
WO2010070022A1 (de) * | 2008-12-19 | 2010-06-24 | Boehringer Ingelheim International Gmbh | Neue verbindungen |
US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
EP2305647A1 (en) | 2009-09-18 | 2011-04-06 | PAION UK Limited | Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process |
US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
WO2012058645A1 (en) | 2010-10-29 | 2012-05-03 | Biogen Idec Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
EP2654423B1 (en) | 2010-12-22 | 2016-12-07 | Merck Sharp & Dohme Corp. | Fused heterocyclic azaindane carboxamide cgrp receptor antagonists |
WO2012087777A1 (en) * | 2010-12-22 | 2012-06-28 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide cgrp receptor antagonists |
US9708276B2 (en) | 2011-10-12 | 2017-07-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer |
SI2820016T1 (sl) | 2012-02-27 | 2017-11-30 | Bristol-Myers Squibb Company | N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h- ciklohepta (b)piridin-9-il-4-(2-okso-2, 3-dihidro-1h-imidazo(4,5-b) piridin-1-il) piperidin-1-karboksilat, hemisulfatna sol |
AR094963A1 (es) | 2013-03-04 | 2015-09-09 | Ono Pharmaceutical Co | Reacción de oxidación excelente en el índice de conversión |
CA2924527C (en) | 2013-09-20 | 2022-07-12 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Compounds for treating prostate cancer |
US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
GB201417707D0 (en) | 2014-10-07 | 2014-11-19 | Viral Ltd | Pharmaceutical compounds |
GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
EP3696181A1 (en) | 2015-11-20 | 2020-08-19 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
SG10201913587WA (en) | 2016-02-05 | 2020-02-27 | Denali Therapeutics Inc | Inhibitors of receptor-interacting protein kinase 1 |
US10980806B2 (en) | 2016-03-24 | 2021-04-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
PL3552017T3 (pl) | 2016-12-09 | 2022-08-08 | Denali Therapeutics Inc. | Związki użyteczne jako inhibitory RIPK1 |
EP3366286A1 (en) | 2017-02-22 | 2018-08-29 | Johannes Keller | Compounds for treating sepsis |
CN108341821B (zh) * | 2018-04-10 | 2020-10-27 | 千辉药业(安徽)有限责任公司 | 一种盐酸依匹斯汀的合成方法 |
SG11202102053VA (en) | 2018-09-18 | 2021-04-29 | Goldfinch Bio Inc | Pyridazinones and methods of use thereof |
CN113939295A (zh) * | 2019-03-20 | 2022-01-14 | 金翅雀生物公司 | 哒嗪酮及其使用方法 |
GB201908420D0 (en) | 2019-06-12 | 2019-07-24 | Heptares Therapeutics Ltd | Cgrp antagonist compounds |
US20210130445A1 (en) * | 2019-07-05 | 2021-05-06 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Botulinum Toxins for the Treatment of Inflammatory and Neurologic Disorders |
WO2021005494A1 (en) * | 2019-07-05 | 2021-01-14 | Allergan Pharmaceuticals International Limited | Cgrp antagonists and clostridial derivatives for the treatment of neuropsychiatric and neurological disorders |
US20240018144A1 (en) * | 2020-10-12 | 2024-01-18 | The Regents Of The University Of Michigan | Synthesis of EGFR Modulators |
IL314082A (en) | 2022-01-12 | 2024-09-01 | Denali Therapeutics Inc | Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000018764A1 (en) | 1998-09-30 | 2000-04-06 | Merck Sharp & Dohme Limited | Benzimidazolinyl piperidines as cgrp ligands |
NZ537315A (en) * | 2002-06-05 | 2006-04-28 | Bristol Myers Squibb Co | Calcitonin gene related peptide receptor antagonists |
-
2005
- 2005-10-12 KR KR1020077008363A patent/KR20070062997A/ko not_active Application Discontinuation
- 2005-10-12 AT AT05804366T patent/ATE411323T1/de not_active IP Right Cessation
- 2005-10-12 BR BRPI0517418-0A patent/BRPI0517418A/pt not_active Application Discontinuation
- 2005-10-12 DE DE602005010463T patent/DE602005010463D1/de active Active
- 2005-10-12 WO PCT/US2005/036763 patent/WO2006044504A1/en active Application Filing
- 2005-10-12 US US11/665,523 patent/US8039460B2/en active Active
- 2005-10-12 CA CA002583536A patent/CA2583536A1/en not_active Abandoned
- 2005-10-12 EP EP05804366A patent/EP1802637B1/en active Active
- 2005-10-12 AU AU2005295729A patent/AU2005295729B2/en not_active Ceased
- 2005-10-12 RU RU2007117741/04A patent/RU2007117741A/ru not_active Application Discontinuation
- 2005-10-12 MX MX2007004393A patent/MX2007004393A/es not_active Application Discontinuation
- 2005-10-12 JP JP2007536866A patent/JP4913061B2/ja not_active Expired - Fee Related
-
2007
- 2007-03-29 IL IL182317A patent/IL182317A0/en unknown
- 2007-05-11 NO NO20072435A patent/NO20072435L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP4913061B2 (ja) | 2012-04-11 |
WO2006044504A1 (en) | 2006-04-27 |
US20080113966A1 (en) | 2008-05-15 |
JP2008515991A (ja) | 2008-05-15 |
EP1802637B1 (en) | 2008-10-15 |
ATE411323T1 (de) | 2008-10-15 |
CA2583536A1 (en) | 2006-04-27 |
MX2007004393A (es) | 2007-04-25 |
EP1802637A1 (en) | 2007-07-04 |
KR20070062997A (ko) | 2007-06-18 |
AU2005295729B2 (en) | 2011-07-14 |
US8039460B2 (en) | 2011-10-18 |
AU2005295729A1 (en) | 2006-04-27 |
WO2006044504A8 (en) | 2006-06-08 |
IL182317A0 (en) | 2007-07-24 |
RU2007117741A (ru) | 2008-11-20 |
BRPI0517418A (pt) | 2008-10-07 |
DE602005010463D1 (de) | 2008-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE411323T1 (de) | Cgrp-rezeptorantagonisten | |
ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
ATE507880T1 (de) | Cgrp-rezeptorantagonisten | |
DE602004013563D1 (de) | Rantagonisten | |
TW200505903A (en) | CGRP receptor antagonists | |
WO2006041830A3 (en) | Cgrp receptor antagonists | |
ATE516803T1 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
ATE464305T1 (de) | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors | |
ATE535514T1 (de) | Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten | |
ATE537153T1 (de) | Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors | |
ATE509019T1 (de) | Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten | |
ATE463245T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
ATE518852T1 (de) | Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten | |
WO2007016087A3 (en) | Heterocyclic benzodiazepine cgrp receptor antagonists | |
ATE466853T1 (de) | Cgrp-rezeptorantagonisten | |
WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |